Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024. In the quarter to June 2026, revenue grew 4.80%, EPS grew 33.8%, free cash flow grew 13.1% and total debt fell 1.23%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five.
Follow ZBH
Zimmer Biomet Holdings, Inc. (ZBH) P/B ratio
As of 16 October 2026, Zimmer Biomet Holdings, Inc. (ZBH) trades at a P/B ratio of 1.4×. Over the past ten years it has ranged from 1.2× (May 2026) to 3.0× (February 2015); the current reading is higher than 6% of that period. That is below the Medical Devices industry median of 2.3× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.4× | (18.51%) |
| FY2024 | 1.7× | (15.23%) |
| FY2023 | 2.0× | (8.55%) |
| FY2022 | 2.2× | 9.20% |
| FY2021 | 2.0× | (19.98%) |
| FY2020 | 2.5× | 5.55% |
| FY2019 | 2.4× | 32.34% |
| FY2018 | 1.8× | (12.30%) |
| FY2017 | 2.1× | (0.13%) |
| FY2016 | 2.1× | 9.93% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 1.3× | (5.80%) |
| Mar 2026 | 1.4× | (0.78%) |
| Dec 2025 | 1.4× | (8.32%) |
| Sep 2025 | 1.5× | 6.14% |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.4× |
| ZBH Zimmer Biomet Holdings, Inc. | 1.4× |
| PHG Koninklijke Philips N.V. compare | 1.8× |
| GMED Globus Medical, Inc. compare | 2.2× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.5× |
| GEHC GE HealthCare Technologies Inc. compare | 2.9× |
| STE STERIS plc compare | 3.0× |
| PEN Penumbra, Inc. compare | 8.2× |
| DXCM DexCom, Inc. compare | 12.5× |
| Medical Devices industry median | 2.3× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on ZBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement